Top of this page
Skip navigation, go straight to the content

 

Neupro® (Parkinson's disease)

In Europe, Neupro® is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or "on-off" fluctuations).

Neupro® (rotigotine transdermal system) is available under the form of a transdermal patch for the treatment of Parkinson's disease. Neupro® provides stable, continuous drug delivery 24 hours a day. Neupro® improves patient functionality and movement and the therapeutic benefit is independent of age, gender and race.

Neupro® may be prescribed for use in adults and elderly.